These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1830547)

  • 1. [Different effects on dopamine receptors D1 and D2 following long-term usage of L-dopa].
    Wei D
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Apr; 24(2):104-7, 125. PubMed ID: 1830547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.
    Robertson GS; Robertson HA
    J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chronic levodopa on D1 and D2 receptor-mediated striatal output.
    Engber TM; Susel Z; Weick BG; Walters JR; Chase TN
    Neurochem Int; 1992 Mar; 20 Suppl():255S-260S. PubMed ID: 1365437
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D1/D2 dopamine receptor stimulation by L-dopa. A [14C]-2-deoxyglucose autoradiographic study.
    Trugman JM; James CL; Wooten GF
    Brain; 1991 Jun; 114 ( Pt 3)():1429-40. PubMed ID: 1829645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Mela F; Marti M; Bido S; Cenci MA; Morari M
    Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions.
    Khan SM; Smith TS; Bennett JP
    J Neurosci Res; 1999 Jan; 55(1):71-9. PubMed ID: 9890435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy.
    Ariano MA; Engber TM; Susel Z; Chase TN
    Exp Neurol; 1991 Apr; 112(1):112-8. PubMed ID: 1826481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP; Markstein R
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.
    Taylor JL; Bishop C; Ullrich T; Rice KC; Walker PD
    Neuropharmacology; 2006 May; 50(6):761-8. PubMed ID: 16434065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.
    Proença MB; Dombrowski PA; Da Cunha C; Fischer L; Ferraz AC; Lima MM
    Neuropharmacology; 2014 Jan; 76 Pt A():118-26. PubMed ID: 24012539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal 6-OHDA lesions differentially affect striatal D1 and D2 receptors.
    Neal BS; Joyce JN
    Synapse; 1992 May; 11(1):35-46. PubMed ID: 1351321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.